Physician profile
Thomas G Munyon
NPI 1568481588
$2,317.36
in general payments reported to CMS, 2019-2025
19 companies · $700 in 2025
The $700 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $349 · 2021: $332 · 2022: $240 · 2023: $263 · 2024: $251 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,214.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $517.85 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $394.19 | 2021-2025 | Nemluvio, Dysport |
| Leo Pharma INC. | $331.10 | 2025 | Adbry, Anzupgo |
| Genzyme Corporation | $265.07 | 2019-2023 | |
| Abbvie INC. | $236.34 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $168.39 | 2019-2023 | |
| Incyte Corporation | $76.38 | 2025 | Opzelura |
| Lilly USA, LLC | $56.65 | 2019-2022 | |
| Janssen Biotech, INC. | $48.53 | 2022-2023 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $41.51 | 2024 | Sotyktu |
| Dermira, INC. | $39.10 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $24.57 | 2024 | Ycanth |
| Celgene Corporation | $23.38 | 2019 | |
| Biofrontera INC. | $21.56 | 2019 | |
| Philips North America LLC | $20.72 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $20.29 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $16.30 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $15.43 | 2023 | Dupixent |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Munyon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.